Guided Therapeutics (GTHP) Total Current Liabilities (2016 - 2025)
Guided Therapeutics (GTHP) has disclosed Total Current Liabilities for 16 consecutive years, with $6.6 million as the latest value for Q4 2025.
- Quarterly Total Current Liabilities rose 7.81% to $6.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.6 million through Dec 2025, up 7.81% year-over-year, with the annual reading at $6.6 million for FY2025, 7.81% up from the prior year.
- Total Current Liabilities hit $6.6 million in Q4 2025 for Guided Therapeutics, up from $6.5 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $9.2 million in Q1 2021 to a low of $4.0 million in Q1 2023.
- Historically, Total Current Liabilities has averaged $5.7 million across 5 years, with a median of $5.7 million in 2021.
- Biggest five-year swings in Total Current Liabilities: crashed 40.96% in 2022 and later skyrocketed 33.45% in 2024.
- Year by year, Total Current Liabilities stood at $5.7 million in 2021, then dropped by 14.49% to $4.9 million in 2022, then fell by 1.23% to $4.8 million in 2023, then rose by 27.99% to $6.2 million in 2024, then grew by 7.81% to $6.6 million in 2025.
- Business Quant data shows Total Current Liabilities for GTHP at $6.6 million in Q4 2025, $6.5 million in Q3 2025, and $6.4 million in Q2 2025.